Anupam Rasayan Q4FY26 Revenue Up 26% to ₹6,392 Mn, FY26 Revenue Surges 65% to ₹23,836 Mn
Anupam Rasayan reported Q4FY26 revenue of ₹6,392 Mn (up 26% YoY) and FY26 revenue of ₹23,836 Mn (up 65% YoY). FY26 PAT surged 39% to ₹2,222 Mn. The company highlighted the strategic acquisition of Jayhawk Fine Chemicals in the US and a definitive agreement to acquire Bliss GVS Pharma.
The announcement includes key financial results with substantial year-on-year growth and details on significant strategic acquisitions, which are expected to have a material impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue for both the quarter and the full financial year, along with a significant increase in full-year profit after tax. Strategic acquisitions were also highlighted as positive developments.
Anupam Rasayan India Ltd. announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a Total Revenue of ₹6,392 Mn for Q4FY26, a 26% increase year-on-year from ₹5,057 Mn in Q4FY25. For the full financial year FY26, Total Revenue grew by 65% to ₹23,836 Mn, compared to ₹14,485 Mn in FY25.
EBITDA for Q4FY26 stood at ₹1,407 Mn, a decrease of 6% from ₹1,500 Mn in Q4FY25, resulting in an EBITDA margin of 22%. For FY26, EBITDA increased by 32% to ₹5,430 Mn from ₹4,123 Mn in FY25, with an EBITDA margin of 23% for the full year.
Profit After Tax (PAT) for Q4FY26 was ₹560 Mn, down from ₹629 Mn in Q4FY25. However, for FY26, PAT saw a significant increase of 39%, reaching ₹2,222 Mn compared to ₹1,600 Mn in FY25.
Mr. Anand Desai, Managing Director, stated that FY26 was a landmark year, marked by strong operational execution, strategic expansion, and progress in building a globally integrated specialty chemicals and CDMO platform. He highlighted the company's highest-ever annual sales and operating cash flow performance, driven by new product commercialization, new multinational customers, and expanding business verticals. The acquisition of Jayhawk Fine Chemicals in the US was a key strategic milestone, contributing strong proforma revenue of US$ 95 Mn and strengthening the global manufacturing footprint and CDMO platform. An agreement to acquire Bliss GVS Pharma was also signed, which is expected to further enhance pharmaceutical value chain capabilities and create synergies.
Looking ahead, the company is well-positioned for growth, supported by increasing contributions from the Performance Materials and Pharma segments, a strong product pipeline, and expanding global customer engagements.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.